Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, Sim SH, Ueno T, Futamura M, Toi M, Fujiwara Y, Ahn SG, Lee JE, Park YH, Takao S, Oba MS, Kitagawa Y, Nishiyama M.
Imoto S, et al. Among authors: ueno t.
Breast Cancer. 2023 May;30(3):412-423. doi: 10.1007/s12282-023-01436-7. Epub 2023 Jan 23.
Breast Cancer. 2023.
PMID: 36689066